Biotechnology Days after the European Commission (EC) granted approval, the UK’s Medicines and Healthcare Regulatory Agency (MHRA) has approved Sarclisa (isatuximab) alongside bortezomib, lenalidomide, and dexamethasone (VRd), for newly-diagnosed multiple myeloma patients (NDMM) ineligible for autologous stem cell transplant (ASCT). 29 January 2025